Navigation Links
Cellectis and Regeneron Sign an Agreement Over the use of Homologous Recombination Technology
Date:7/3/2008

BIOCITECH, France, July 3 /PRNewswire-FirstCall/ -- Cellectis SA today announced the signature of an agreement with Regeneron Pharmaceuticals, Inc. over the use of Cellectis' patents covering certain uses of homologous recombination for the generation of innovative human therapies, including the development of fully human monoclonal antibodies. As part of the agreement, Cellectis will receive an upfront of 12,450,000$ from Regeneron. In addition, Regeneron will invest in Cellectis' equity.

The agreement resolves a dispute between the two companies related to the interpretation of a license agreement entered into by and between Cellectis and Regeneron in December 2003 pursuant to which Regeneron licensed certain patents and patent applications relating to a process for the specific replacement of a copy of a gene in the receiver genome by homologous recombination. Pursuant to the agreement, Regeneron will make an up-front payment to Cellectis in the amount of $12,450,000. In addition, Regeneron will pay Cellectis a low single-digit royalty based on revenue received by Regeneron from any future licenses or sales of Regeneron's VelociGene(R) or VelocImmune(R) products and services. No royalties are payable with respect to Regeneron's VelocImmune license agreements with AstraZeneca UK Limited and Astellas Pharma Inc. or Regeneron's November 2007 collaboration agreement with sanofi-aventis. Moreover, due to other considerations in the agreement, no royalties are payable on any revenue from commercial sales of antibodies from Regeneron's VelocImmune technology.

Regeneron and Cellectis also entered into a Subscription Agreement pursuant to which Regeneron will acquire 368,301 ordinary shares of Cellectis, par value EUR 0.05 per share, at a price of EUR 8.63 per share, for a total of EUR 3,178,437.63. The subscription is contingent upon the prior approval of the board of directors of Cellectis and by the shareholders of Cellectis at an extraordinary general meeting to be held no later than October 30, 2008.

About the licensed patents:

The agreement relates to Institut Pasteur's patents covering certain uses of homologous recombination (US patents #6 528 313, 6 638 768 and 6 528 314, Japanese patents #3059481, #3298842 and #3298864 and European patents EP #419 621 and #682 112). As the exclusive licensee of these patents, Cellectis has access to the process of targeted integration of DNA sequences.

For further information, please contact:

Cellectis S.A.

David J.D. Sourdive, Ph. D

VP Corporate Development

Tel.: +33-(0)-1-41-83-99-00

e-mail: sourdive@cellectis.com

http://www.cellectis.com

Alize Public Relations

Caroline Carmagnol

Tel.: +33-(0)-6-64-18-99-59

e-mail: caroline@alizerp.com


'/>"/>
SOURCE Cellectis SA
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Cellectis Sues Precision BioSciences for Infringement of its Patents Concerning Meganuclease Technology
2. BioSpace to Host Regeneron Pharmaceuticals Career Fair in Whippany, New Jersey
3. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
4. Cepheid Enters Into Five-Year Agreement With Northrop Grumman for the Purchase of Anthrax Test Cartridges for Use in United States Postal Service Biohazard Detection Systems
5. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
6. International Isotopes Inc. Announces Completion of an Exclusive Distributor Agreement for Sales of New Style Transportation Containers
7. China-Biotics, Inc. Signs Intention Agreement to Supply Probiotics to Bright Dairy & Food Co., Ltd.
8. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
9. Pfizer and Bristol-Myers Squibb Finalize Agreement for Worldwide Collaboration on Metabolic Disorders Program
10. Medco Announces Agreement to Acquire Diabetes Care Leader PolyMedica in Transaction Valued at $1.5 Billion
11. Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... Rocky Hill, Conn. (PRWEB) , ... April 28, ... ... source of financing and ongoing support for Connecticut's innovative, growing companies, today announced ... early-stage digital health and financial technology (fintech) companies. , “VentureClash looks ...
(Date:4/27/2016)... ... April 27, 2016 , ... Cambridge Semantics, the leading ... today announced that it has been named to The Silicon Review’s “20 Fastest Growing ... other markets, Cambridge Semantics serves the needs of end users facing some of the ...
(Date:4/27/2016)... 27, 2016 NanoStruck Technologies ... NSKQB) ( Frankfurt : 8NSK) gibt ... vom 13. August 2015 die Genehmigung von der ... zusätzliche 200.000.000 Einheiten auf 400.000.000 Einheiten zu erhöhen, ... Davon wurden 157.900.000 Einheiten mit dem ersten Teil ...
(Date:4/27/2016)... , ... April 27, 2016 , ... ... PhD to its Scientific Advisory Board. Dr. Lamka will assist PathSensors in expanding ... detection. , PathSensors deploys the CANARY® test platform for the detection of ...
Breaking Biology Technology:
(Date:3/17/2016)... , March 17, 2016 ABI Research, ... forecasts the global biometrics market will reach more ... 118% increase from 2015. Consumer electronics, particularly smartphones, ... fingerprint sensors anticipated to reach two billion shipments ... Dimitrios Pavlakis , Research Analyst at ABI ...
(Date:3/11/2016)... HANOVER, Germany , March 11, 2016 ... - Cross reference: Picture is available at AP Images ( ... scanner from DERMALOG will be used to produce the new refugee ... of other biometric innovations, at CeBIT in Hanover ... LF10 scanner from DERMALOG will be used to produce the new ...
(Date:3/9/2016)... Nigeria . Recently, ... 23,000 public service employees either did not exist with ... unlawfully.    --> Nigeria . ... than 23,000 public service employees either did not exist ... salary unlawfully.    --> DERMALOG, the biometrics ...
Breaking Biology News(10 mins):